Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KIS siRNA refers to a small interfering RNA molecule specifically designed to silence the **KIS gene** (Kinase Interacting with Stathmin, also known as CDKN1B-interacting protein), utilizing the RNA interference (RNAi) pathway. siRNAs are synthetic double-stranded RNA molecules, generally 20–24 nucleotides in length, that post-transcriptionally silence gene expression by guiding the RNA-induced silencing complex (RISC) to degrade mRNA with a fully complementary sequence. The antisense (guide) strand of the siRNA mediates the sequence-specific degradation of the target mRNA, thereby preventing translation and ultimately reducing protein production[1][2][3][4][5][6][7]. KIS siRNA would be a sequence-specific agent for research or therapeutic applications seeking to downregulate KIS expression through targeted mRNA degradation. The precise design and specificity minimize off-target effects and make siRNA a potent tool for gene knockdown in research or potential clinical applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KIS siRNA.